Maki.vc

Maki.vc is a Helsinki-based fund with a more eclectic mandate than most of its Nordic peers: it backs deep tech and brand-driven founders, which means the same fund underwrites bio-manufacturing companies and consumer brands with comparable seriousness. That breadth is unusual and signals a partner group comfortable holding multiple distinct theses at once.

The healthcare thesis covers AI/ML in healthcare and biotech, with a bias toward founders working at the technical or scientific edge rather than the workflow-software middle. The firm is comfortable with bio-manufacturing, algorithmic healthcare, and other technically demanding categories that require patience and a tolerance for long product cycles. Specific portfolio companies are not enumerated in the source material, so founders should ask for direct references in diligence, particularly to understand how the firm has engaged in healthcare-specific milestones.

Maki.vc invests at Pre-Seed, Seed, and Series A, with checks of one to five million dollars. The geographic focus is the Nordic region with selective activity beyond, and the firm operates as a credible early lead in technically deep rounds. For founders building biotech or algorithmic healthcare companies anchored in Finland or the broader Nordic region, Maki.vc is one of a small set of funds that will engage substantively at the earliest stages, and its ability to follow into Series A provides useful continuity.

The team is built around partners with backgrounds in operating, engineering, and venture investing, with explicit interest in both deep tech and brand-driven business models. Specific partner names are not provided in the source material, and founders should clarify which partner leads biotech and AI healthcare directly.

The right founders for Maki.vc are technically deep teams in biotech, bio-manufacturing, and applied AI in healthcare, where the firm’s appetite for long product cycles and scientific risk creates real fit. The wrong founders are application-layer software teams expecting consumer-style growth metrics, where the firm’s lens may not align with the actual development pace. Founders should arrive with a credible scientific or technical roadmap, a realistic view of capital requirements through clinical or manufacturing milestones, and a clear sense of which Nordic and European syndicate partners would join later rounds. Maki.vc is comfortable with patience and tends to be skeptical of compressed timelines that do not match the underlying biology or engineering.